Biofrontera
(Note: Immediately after this offering, Biofrontera AG, our parent company and sole existing stockholder immediately prior to this offering, will own about 72.7% of our outstanding shares of common stock.) We are a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, in particular, diseases caused primarily by […]
October 13, 2021 Read More